Subscribe to RSS
DOI: 10.1055/a-2041-2986
Identification of ADA as a Biomarker for Atypical Epstein Barr Virus Infection in Children
Funding Information Natural Science Foundation of Suzhou City — http://dx.doi. org/10.13039/100016803; SKJY2021106![](https://www.thieme-connect.de/media/klinpaed/202304/lookinside/thumbnails/1666_10-1055-a-2041-2986-1.jpg)
Abstract
Objective This study aims to explore the ability of adenosine deaminase (ADA) to discriminate atypical Epstein Barr virus (EBV) infection in children from acute febrile illness.
Methods All children admitted to the Children’s Hospital of Soochow University between 2018 and 2019, who were acute febrile patients and subjected to the plasma EBV-DNA polymerase chain reaction (PCR) and indirect immunofluorescence (IIF) assay for EBV-specific antibodies assays. The diagnostic value of each detection index was compared by the area under the ROC curve.
Results In children with atypical Epstein Barr virus infection, the sensitivity, specificity, positive predictive value, negative predictive value and Youden index were 62.87%, 100.00%,100.00%, 61.73% and 0.63 for EBV-DNA PCR assay, 80.84%, 100.00%, 100.00%, 75.76% and 0.81 for VCA-IgG avidity and 89.22%, 87.00%, 91.98%, 82.86% and 0.76 for ADA. VCA-IgG avidity (AUC=0.904, P<0.01) and ADA (AUC=0.881, P<0.01) assays had the great diagnostic efficiency. In addition, the sensitivity, specificity and AUC were 92.75%,91.43% and 0.921(95%CI: 0.856–0.985) for ADA in the course≤3 days group, respectively.
Conclusions ADA has a good diagnostic value in the early stage of atypical EBV infection, and is not affected by primary EBV infection and reactivation.
Schlüsselwörter Adenosine deaminase, Epstein -Barr virus, Biomarker, children.
Publication History
Article published online:
28 April 2023
© 2023. Thieme. All rights reserved.
Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart,
Germany
-
References
- 1 de Thé G, Day N, Geser A. et al. Epidemiology of the Epstein-Barr virus infection and associated tumors in man. Bibl Haematol 1975; 216-220
- 2 Thompson MP, Kurzrock R. Epstein-Barr virus and cancer. Clin Cancer Res 2004; 10: 803-821
- 3 Balfour HH, Verghese P. Primary Epstein-Barr virus infection: impact of age at acquisition, coinfection, and viral load. J Infect Dis 2013; 207: 1787-1789
- 4 Dowd JB, Palermo T, Brite J. et al. Seroprevalence of Epstein-Barr virus infection in U.S. children ages 6-19, 2003-2010. PLoS One 2013; 8: e64921
- 5 Cohen JI. Epstein-Barr virus infection. N Engl J Med 2000; 343: 481-492
- 6 Nowalk A, Green M. Epstein-Barr virus. Microbiol Spectr 2016; 4
- 7 Shi T, Huang L, Chen Z. et al. Characteristics of primary Epstein-Barr virus infection disease spectrum and its reactivation in children, in Suzhou, China. J Med Virol 2021; 93: 5048-5057
- 8 Hurt C, Tammaro D. Diagnostic evaluation of mononucleosis-like illnesses. Am J Med 2007; 120: 911.e1-8
- 9 Kanakry JA, Hegde AM, Durand CM. et al. The clinical significance of EBV DNA in the plasma and peripheral blood mononuclear cells of patients with or without EBV diseases. Blood 2016; 127: 2007-2017
- 10 Antonioli L, Colucci R, La Motta C. et al. Adenosine deaminase in the modulation of immune system and its potential as a novel target for treatment of inflammatory disorders. Curr Drug Targets 2012; 13: 842-862
- 11 Mejer J, Nygaard P, Cohn J. et al. Adenosine deaminase, purine nucleoside phosphorylase and 5’-nucleotidase activities in infectious mononucleosis. Adv Exp Med Biol 1984; 165: 249-252
- 12 Schiavetti A, Gonfiantini M, Varrasso G. et al. Atypical Epstein-Barr-virus infection in a 5-year-old girl. Minerva Pediatr 2009; 61: 115-117
- 13 Shi J, Ma W, Li W. Epidemiologic features of children with Epstein-Barr virus associated diseases in Hangzhou, China. J Med Virol 2020; 92: 1277-1282
- 14 Niller HH, Bauer G. Epstein-Barr virus: clinical diagnostics. Methods Mol Biol 2017; 1532: 33-55
- 15 AbuSalah M, Gan SH, Al-Hatamleh M. et al. Recent advances in diagnostic approaches for Epstein-Barr virus. Pathogens 2020; 9: 226
- 16 Shi T, Huang L, Luo L. et al. Diagnostic value of serological and molecular biological tests for infectious mononucleosis by EBV in different age stages and course of the disease. J Med Virol 2021; 93: 3824-3834
- 17 Singh L, Javali M, Mehta A. et al. Study of cerebrospinal fluid levels of lactate, lactate dehydrogenase and adenosine deaminase in the diagnosis and outcome of acute meningitis. Neurol Res 2022; 44: 463-467
- 18 Delemarre EM, van Hoorn L, Bossink A. et al. Serum biomarker profile including CCL1, CXCL10, VEGF, and adenosine deaminase activity distinguishes active from remotely acquired latent tuberculosis. Front Immunol 2021; 12: 725447
- 19 Bruu AL, Hjetland R, Holter E. et al. Evaluation of 12 commercial tests for detection of Epstein-Barr virus-specific and heterophile antibodies. Clin Diagn Lab Immunol 2000; 7: 451-456
- 20 Zavialov AV, Gracia E, Glaichenhaus N. et al. Human adenosine deaminase 2 induces differentiation of monocytes into macrophages and stimulates proliferation of T helper cells and macrophages. J Leukoc Biol 2010; 88: 279-290
- 21 Ghaderi B, Amini S, Maroofi F. et al. Adenosine deaminase activity in chronic lymphocytic leukemia and healthy subjects. Iran J Cancer Prev 2016; 9: e5069
- 22 Naval-Macabuhay I, Casanova V, Navarro G. et al. Adenosine deaminase regulates Treg expression in autologous T cell-dendritic cell cocultures from patients infected with HIV-1. J Leukoc Biol 2016; 99: 349-359